Dr. Mirza On The Phase Iii Nova Trial In Ovarian Cancer

Dr. Mirza on the Phase III NOVA Trial in Ovarian Cancer

Dr. Mirza on the Rationale for the AVANOVA Trial in Recurrent Ovarian Cancer

Results of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer

Trial design of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer

Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancer

Dr. Mirza on Final Data of the NSGO-AVANOVA2/ENGOT-OV24 Trial in Ovarian Cancer

Dr. Mirza Discusses Niraparib Dose Modifications for Ovarian Cancer Patients With Low Body Weight

Dr. Mirza on the ENGOT-OV42-NSGO/AVANOVA-Triplet Trial in Recurrent Ovarian Cancer

Comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer

Dr. Mirza on the Evolving Treatment Landscape in Recurrent Ovarian Cancer

Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian Cancer

Treating Ovarian Cancer With Niraparib: The NOVA Trial

Dr. Mirza on Efficacy of Niraparib/Bevacizumab Combo in Recurrent Ovarian Cancer

ESMO 2019: Dr. Mirza on Important Trials with PARP Inhibitors in Ovarian Cancer

Niraparib Shows Positive Data, Requires Different Dosing in Ovarian Cancer

Targeted Oncology

Dr. Mirza on the Implications of the NSGO-AVANOVA2/ENGOT-OV24 Trial in Ovarian Cancer

Combination therapy to treat ovarian cancer: promising results from the ANANOVA trial

Dr. Mirza on Niraparib Efficacy Across Ovarian Cancer Subgroups

Dr. Mirza on Impact of Niraparib in Ovarian Cancer

NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer patients